SASH-B: SODIUM ACCUMULATION STUDY IN HAEMODIALYSIS: BRAIN STUDY

Sponsor
University Hospitals of Derby and Burton NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05966116
Collaborator
University of Nottingham (Other)
10
1
12
0.8

Study Details

Study Description

Brief Summary

The aim of the research study is to look at a new type of MRI scanning that can measure the amount of sodium in different parts of the body. Sodium (or 'salt') levels are very important in maintaining health, and high levels lead to high blood pressure. This is very important to patients with kidney disease, as the kidney is the main organ that regulates the amount of sodium in your body. We can measure sodium levels in the blood, but this does not tell us how much sodium is present in other areas of your body. Previously, we have not been able to measure this at all. Sodium MRI (Na-MRI) is a new type of MRI scanning that can directly measure sodium in other parts of body such as skin, muscles, kidneys, and brain. We believe that this will help to guide treatment in patients with kidney disease who are on haemodialysis, but we need to perform research studies to prove the benefits.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Haemodialysis (HD) sustains life in patients with end-stage kidney disease (ESKD) but is associated with a marked increase in cognitive impairment, being three times more common and presenting at a younger age. The predominant features of cognitive impairment associated with HD are loss of executive function, including higher processing such as planning, task prioritisation and self-regulation. The mechanism for development and acceleration of cognitive impairment on dialysis is not well understood, however hypertension and cardiovascular disease are likely to play a significant role, alongside changes in brain perfusion as a result of dialysis itself, which has been shown in a prior study using PET-CT.

    Sodium balance is normally regulated by the kidneys in health, but has to be achieved by sodium removal during HD for those with ESKD. Recent evidence suggests that accumulation of sodium in tissue may be a critical factor impacting the development of hypertension and cardiovascular disease (CVD) in patients with ESKD. Non-invasive methods are therefore required to study tissue sodium accumulation in this context.

    23Na MRI has the potential to provide complementary quantitative parameters of tissue health, in a non-invasive manner. Sodium homeostasis is central to maintenance of human physiology, providing an index of cellular integrity and energy status. The maintenance of sodium gradients across the cell membrane, by the Na+/K+ ATPase pump, enables 23Na MRI to distinguish between different environments within organs, providing a biomarker of disease status, notably kidney disease, hypertension, and brain disorders.

    Previously, traditional proton (1H) magnetic resonance imaging (MRI) in dialysis patients demonstrated a decrease in grey matter T1 and an accompanying increase in white matter T1 when comparing scans before, during and after dialysis, In this context, T1 can be thought of as a marker of water content. This demonstrates that changes in the brain occur as a direct consequence of dialysis, with fluid and sodium shifts across cellular compartments the most likely explanation. This is important, as it suggests a novel mechanism by which dialysis may cause reductions in cognitive function. However, this needs further study to establish these mechanisms with more confidence.

    At the SPMIC, a dual tuned proton(1H)/sodium(23Na) volume head RF coil for 23Na imaging of the brain has been installed and interfaced; and imaging methods to perform 23Na MRI of the brain have been optimised.

    This study proposes to utilise 23Na MRI of the brain along with proton measures of T1, before and after dialysis within existing experimental set-up at SPMIC. This will provide new insights into the direct effects of dialysis on brain sodium levels, and in turn deepen our understanding of the link between sodium, fluid overload, dialysis and the brain.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    10 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    SODIUM ACCUMULATION STUDY IN HAEMODIALYSIS: BRAIN STUDY
    Anticipated Study Start Date :
    Sep 1, 2023
    Anticipated Primary Completion Date :
    Aug 1, 2024
    Anticipated Study Completion Date :
    Sep 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Proportion of brain images that can be analysed for sodium levels [12 months]

      success criterion > 85%

    Secondary Outcome Measures

    1. Change in grey and white matter sodium levels [12 months]

      comparing before and after dialysis

    2. Association between change in brain sodium levels to proton MRI measures [12 months]

      grey/white matter volume, T1

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age 50-75 years inclusive

    • Male and female patients with CKD stage 5 receiving chronic haemodialysis

    • Patient has been dialysis dependent for at least 3 months

    • Must be able to follow simple instruction in English (on safety ground for MRI scans) and be able to understand the nature and requirements of the study

    Exclusion Criteria:
    • Active infection or malignancy

    • Amputee

    • Pregnancy

    • Contraindication to MRI scanning including claustrophobia, pacemaker, metallic implants etc

    • Unable or unwilling to provide informed consent

    • Medical conditions or overall physical frailty precludes scan session in opinion of investigator

    • Any condition which could interfere with the patient's ability to comply with the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre for Kidney Research and Innovation Derby United Kingdom DE22 3NE

    Sponsors and Collaborators

    • University Hospitals of Derby and Burton NHS Foundation Trust
    • University of Nottingham

    Investigators

    • Principal Investigator: Rebecca A Noble, BMBS, The University of Nottingham

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospitals of Derby and Burton NHS Foundation Trust
    ClinicalTrials.gov Identifier:
    NCT05966116
    Other Study ID Numbers:
    • UHDB/2023/055
    First Posted:
    Jul 28, 2023
    Last Update Posted:
    Jul 28, 2023
    Last Verified:
    Jul 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jul 28, 2023